A review of prognostic and predictive biomarkers in breast cancer

• Published in: Clinical and experimental medicine Vol. 23; no. 1; pp. 1 - 16
• Main Authors: Tarighati, Elaheh, Keivan, Hadi, Mahani, Hojjat
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2023; Springer Nature B.V
• Subjects: Antigens; Biomarkers; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - pathology; Cancer therapies; Carcinoma; Chemotherapy; ErbB-2 protein; Female; Hematology; Humans; Internal Medicine; Invasiveness; Mammary gland; Medicine; Medicine & Public Health; Metastases; Oncology; Prognosis; Receptor, ErbB-2; Review Article; Biomarkers; Oncology; Breast cancer; Tumor markers; Micro RNAs
• ISSN: 1591-8890; 1591-9528
• DOI: 10.1007/s10238-021-00781-1

Breast cancer (BC) is a common cancer all over the world that affects women. BC is one of the leading causes of cancer mortality in women, which today has decreased with the advancement of technology and new diagnostic and therapeutic methods. BCs are histologically divided into in situ and invasive carcinoma, and both of them can be divided into ductal and lobular. The main function after the diagnosis of invasive breast cancer is which patient should use chemotherapy, which patient should receive adjuvant therapy, and which should not. If the decision is for adjuvant therapy, the next challenge is to identify the most appropriate treatment or combination of treatments for a particular patient. Addressing the first challenge can be helped by prognostic biomarkers, while addressing the second challenge can be done by predictive biomarkers. Among the molecular markers related to BC, ER, PR, HER2, and the Mib1/Ki-67 proliferation index are the most significant ones and are tightly confirmed in the standard care of all primary, recurrent, and metastatic BC patients. CEA and CA-15–3 antigens are the most valuable markers of serum tumors in BC patients. Determining the series of these markers helps monitor response to the treatment and early detection of recurrence or metastasis. miRNAs have been demonstrated to be intricate in mammary gland growth, proliferation, and formation of BC known to be incriminated in BC biology. By combining established prognostic factors with valid prognostic/predicted biomarkers, we can start the journey to personalized treatment for every recently diagnosed BC patient.